All In Biotech

Drug Trial Radar · NCT02756364

Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy

An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy

Last checked: Nov 20, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 141 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

141

Actual

Start

Jul 28, 2016

Primary completion

Nov 25, 2019

Study completion Nov 25, 2019

Sponsor

Lead sponsor
Calithera Biosciences, IncIndustry
Sponsor type
Industry
First posted
Apr 29, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants treated with single-agent fulvestrant.

Conditions

  • Breast Neoplasms

Interventions

  • FulvestrantDrug

    Fulvestrant IM injection.

  • SapanisertibDrug

    Sapanisertib capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to 40 months

Locations

53 sites in 2 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center, PC

    Mobile, Alabama

  • CBCC Global Research 6501 Truxtun Avenue Bakersfield, CA

    Bakersfield, California

  • St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare

    Fullerton, California

  • UCSD Moores Cancer Center

    La Jolla, California

  • UCLA Hematology/Oncology David Geffen School of Medicine

    Los Angeles, California

  • North County Oncology

    Oceanside, California

  • Torrance Health Association

    Redondo Beach, California

  • PHC-SLO Oncology and Hematology

    San Luis Obispo, California

  • Cancer Center of Santa Barbara With Sansum Clinic

    Santa Barbara, California

  • University of Colorado Cancer Center-Anschutz Cancer Pavilion (ACP)

    Aurora, Colorado

  • St. Mary'S Hospital Regional Cancer Center

    Grand Junction, Colorado

  • Rocky mountain cancer centers LLP

    Lakewood, Colorado

  • Holy Cross Hospital- Bienes Cancer Center

    Fort Lauderdale, Florida

  • Memorial Healthcare System

    Hollywood, Florida

  • Orlando Health Inc.

    Orlando, Florida

  • Ft. Wayne Medical Oncology and Hematology, Inc

    Fort Wayne, Indiana

  • New England Cancer Specialists

    Scarborough, Maine

  • Health Partners Institute Park Nicollet Frauenshuh Cancer Center

    Saint Louis Park, Minnesota

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • New Jersey Hematology & Oncology Associates

    Brick, New Jersey

  • Northern Westchester Hospital Cancer Treatment & Wellness Center

    Mount Kisco, New York

  • Oregon Health and Science University

    Portland, Oregon

  • Texas Oncology, P.A.

    Austin, Texas

  • Texas Oncology - Presbyterian Hospital

    Dallas, Texas

  • Texas Oncology, P.A.

    Dallas, Texas

  • Texas Oncology- South Second Street

    McAllen, Texas

  • Cancer Care Centers of South Texas

    San Antonio, Texas

  • Texas Oncology,PA. Tyler TX, 75702

    Tyler, Texas

  • Virginia Cancer Specialist PC

    Leesburg, Virginia

  • West Virginia University School of Medicine

    Morgantown, West Virginia

  • Complejo Hospitalario Universitario A Coruna

    A Coruña, Spain

  • Centro Oncologico de Galicia

    A Coruña, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Clinic i Provincial

    Barcelona, Spain

  • Hospital De la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital San Pedro de Alcantara

    Cáceres, Spain

  • Hospital Universitari Arnau de Vilanova de Lleida

    Lleida, Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Clinico San Carlos

    Madrid, Spain

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.